Abstract
Radiotherapy remains a central part of the treatment of most primary and secondary brain cancers and contributes significantly to long-term outcomes. Recent developments in radiotherapy technology are providing the opportunity to deliver more accurate, flexible, and individualized treatment in many contexts. This is possible through use of techniques including intensity-modulated radiotherapy, image guidance, and single- and multiple-dose radiosurgery. Current challenges include how best to evaluate the optimal application of these technologies in different patient groups. An additional issue is that an increasing proportion of brain cancer patients treated with radiotherapy is surviving long enough to be at risk of long-term toxicities which are still inadequately understood and difficult to treat.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci U S A. 2003;100(9):5057–62.
Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys. 2004;58(2):331–5.
Short SC, et al. DNA repair after irradiation in glioma cells and normal human astrocytes. Neuro Oncol. 2007;9(4):404–11.
Short SC. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro Oncol. 2011;13(5):487–99.
Salomoni P, Calabretta B. Targeted therapies and autophagy: new insights from chronic myeloid leukemia. Autophagy. 2009;5(7):1050–1.
Nandi S, et al. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res. 2008;68(14):5778–84.
Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.
Chalmers AJ, et al. Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int J Radiat Oncol Biol Phys. 2009;75(5):1511–9.
Powell C, et al. Somnolence syndrome in patients receiving radical radiotherapy for primary brain tumours: a prospective study. Radiother Oncol. 2011;100(1):131–6.
Minniti G, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005;90(2):800–4.
Brada M, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ. 1992;304(6838):1343–6.
Otsuka S, et al. Depletion of neural precursor cells after local brain irradiation is due to radiation dose to the parenchyma, not the vasculature. Radiat Res. 2006;165(5):582–91.
Benczik J, et al. Late radiation effects in the dog brain: correlation of MRI and histological changes. Radiother Oncol. 2002;63(1):107–20.
Panagiotakos G, et al. Long-term impact of radiation on the stem cell and oligodendrocyte precursors in the brain. PLoS One. 2007;2(7):e588.
Marsh JC, et al. Sparing of the neural stem cell compartment during whole-brain radiation therapy: a dosimetric study using helical tomotherapy. Int J Radiat Oncol Biol Phys. 2010;78(3):946–54.
Chuba PJ, et al. Hyperbaric oxygen therapy for radiation-induced brain injury in children. Cancer. 1997;80(10):2005–12.
Gonzalez J, et al. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007;67(2):323–6.
Sherman JH, et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology. 2009;73(22):1924–6.
Truman JP, et al. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One. 2010;5(8):e12310.
Baumert BG, et al. EORTC 22972–26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. Radiother Oncol. 2008;88(2):163–72.
Baumert BG, et al. Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas. Radiother Oncol. 2003;67(2):183–90.
Stall B, et al. Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas. Radiat Oncol. 2010;5:5.
Narayana A, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys. 2006;64(3):892–7.
Khoo VS, et al. Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors. Int J Radiat Oncol Biol Phys. 1999;45(2):415–25.
Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol. 2002;64(3):259–73.
Donato V, et al. Elderly and poor prognosis patients with high grade glioma: hypofractionated radiotherapy. Clin Ter. 2007;158(3):227–30.
Chinot OL. Should radiotherapy be standard therapy for brain tumors in the elderly? Cons. Semin Oncol. 2003;30(6 Suppl 19):68–71.
Rivera AL, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12(2):116–21.
Chamberlain MC, et al. Concurrent cisplatin therapy and iodine 125 brachytherapy for recurrent malignant brain tumors. Arch Neurol. 1995;52(2):162–7.
Prados MD, et al. Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiat Oncol Biol Phys. 1992;24(4):593–7.
Fulton DS, et al. Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study. J Neurooncol. 1992;14(1):63–72.
Fulton DS, et al. Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys. 1984;10(9):1709–12.
Combs SE, et al. Progostic significance of IDH-1 and MGMT in patients with glioblastoma:one step forward and one step back? Radiat Oncol. 2011;13(6):115.
van den Bent MJ. Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin. 2007;25(4):1089–109. ix-x.
Combs SE, et al. Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J Neurooncol. 2005;71(3):319–23.
Grosu AL, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(2):511–9.
van den Bent MJ. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Semin Oncol. 2003;30(6 Suppl 19):39–44.
Karim AB, et al. A randomized trial on dose response in radiation therapy of low grade glioma: EORTC study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549–56.
Smedby KE, et al. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer. 2009;101(11):1919–24.
Rades D, et al. Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases. Strahlenther Onkol. 2008;184(1):30–5.
Chang EL, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole brain radiotherapy: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44.
Mehta MP, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1069–76.
Kocher M. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol. 2011;29(2):134–41.
Patchell RA, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.
Kirby N, et al. Physics strategies for sparing neural stem cells during whole brain radiation treatments. Med Phys. 2011;38(10):5338–44.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Short, S.C. (2013). Radiation Oncology in Brain Cancer. In: Watts, C. (eds) Emerging Concepts in Neuro-Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-458-6_10
Download citation
DOI: https://doi.org/10.1007/978-0-85729-458-6_10
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-457-9
Online ISBN: 978-0-85729-458-6
eBook Packages: MedicineMedicine (R0)